Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
// María Victoria Zelaya 1 , Estela Pérez-Valderrama 1 , Xabier Martínez de Morentin 1 , Teresa Tuñon 2 , Isidro Ferrer 3 , María Rosario Luquin 4 , Joaquín Fernandez-Irigoyen 1,* and Enrique Santamaría 1,* 1 Proteomics Unit, Clinical Neuroproteomics Group, Navarrabiomed, Fundación Miguel Servet, Proteored-ISCIII, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain 2 Pathological Anatomy Department, Navarra Hospital Complex, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain 3 Institut de Neuropatologia, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L’Hospitalet de Llobregat, Spain, CIBERNED (Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas), Spain 4 Laboratory of Regenerative Therapy, Department of Neurology and Neuroscience Division, Centre for Applied Medical Research (CIMA), University of Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain * These authors share senior authorship Correspondence to: Enrique Santamaría, email: // Keywords : Alzheimer, neurodegeneration, olfactory bulb, proteomics, Gerotarget Received : July 16, 2015 Accepted : September 30, 2015 Published : October 28, 2015 Abstract Olfactory dysfunction is present in up to 90% of Alzheimer’s disease (AD) patients. Although deposition of hyperphosphorylated tau and β-amyloid substrates are present in olfactory areas, the molecular mechanisms associated with decreased smell function are not completely understood. We have applied mass spectrometry-based quantitative proteomics to probe additional molecular disturbances in postmortem olfactory bulbs (OB) dissected from AD cases respect to neurologically intact controls (n=20, mean age 82.1 years). Relative proteome abundance measurements have revealed protein interaction networks progressively disturbed across AD stages suggesting an early imbalance in splicing factors, subsequent interrupted cycling of neurotransmitters, alteration in toxic and protective mechanisms of β-amyloid, and finally, a mitochondrial dysfunction together with disturbance in neuron-neuron adhesion. We also present novel molecular findings in the OB in an autopsy cohort composed by Lewy body disease (LBD), frontotemporal lobar degeneration (FTLD), mixed dementia, and progressive supranuclear palsy (PSP) cases ( n = 41, mean age 79.7 years). Olfactory mediators deregulated during the progression of AD such as Visinin-like protein 1, RUFY3 protein, and Copine 6 were also differentially modulated in the OB in LBD, FTLD, and mixed dementia. Only Dipeptidyl aminopeptidase-like protein 6 showed a specific down-regulation in AD. However, no differences were observed in the olfactory expression of this protein panel in PSP subjects. This study demonstrates an olfactory progressive proteome modulation in AD, unveiling cross-disease similarities and differences especially for specific proteins involved in dendritic and axonic distributions that occur in the OB during the neurodegenerative process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STRING v9.1: protein-protein interaction networks, with increased coverage and integration
Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1094 · Cited by 4,398
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 9×
“We have included pathologies with common smell impairment like LBD, and FTLD [1], PSP where olfactory loss occurs to a lesser extent or is absent [1, 35, 36], and mixed dementia (Mix AD VD).”
InfluentialMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 9×
“We have included pathologies with common smell impairment like LBD, and FTLD [1], PSP where olfactory loss occurs to a lesser extent or is absent [1, 35, 36], and mixed dementia (Mix AD VD).”
InfluentialNeuronal calcium mishandling and the pathogenesis of Alzheimer's disease
Bezprozvanny, I., & Mattson, M. P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.005 · Cited by 938
Alafuzoff, I., Arzberger, T., Al‐Sarraj, S., Bodi, I., Bogdanovic, N., Braak, H., Bugiani, O., Del‐Tredici, K., Ferrer, I., Gelpi, E., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00147.x · Cited by 467 · cited 9×
“We have included pathologies with common smell impairment like LBD, and FTLD [1], PSP where olfactory loss occurs to a lesser extent or is absent [1, 35, 36], and mixed dementia (Mix AD VD).”
InfluentialSelf-citationNeuronal organization of olfactory bulb circuits
Nagayama, S., Homma, R., & Imamura, F. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00098 · Cited by 411 · cited 1×
“We have analysed dissected areas that contained multiple cell types [77], thus diluting the proteomic contribution of each specific cell type.”
Brakebusch, C., Seidenbecher, C. I., Asztely, F., Rauch, U., Matthies, H., Meyer, H., Krug, M., Böckers, T. M., Zhou, X., Kreutz, M. R., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.21.7417-7427.2002 · Cited by 264
Neurocan Is Dispensable for Brain Development
Zhou, X.-H., Brakebusch, C., Matthies, H., Oohashi, T., Hirsch, E., Moser, M., Krug, M., Seidenbecher, C. I., Boeckers, T. M., Rauch, U., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5970-5978.2001 · Cited by 206
Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer’s disease
Bobkova, N. V., Garbuz, D. G., Nesterova, I., Medvinskaya, N., Samokhin, A., Alexandrova, I., Yashin, V., Karpov, V., Kukharsky, M. S., Ninkina, N. N., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130779 · Cited by 138 · cited 1×
“com/oncotarget administered of recombinant human HSP70 in murine models of AD has demonstrated dramatic neuroprotective effects [48], suggesting that our experimental workflow is a useful approach to detect and identify practical therapeutic agents for AD treatment.”
Schnurra, I., Bernstein, H.-G., Riederer, P., & Braunewell, K.-H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0432 · Cited by 76
The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer’s disease—old wine in new bottles
Braunewell, K. H. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00020 · Cited by 66 · cited 1×
“It has been proposed that the down-regulation of VILIP1 may attenuate neuronal signaling pathways regulating the neuroplasticity process, contributing to cognitive decline in initial stages of AD [69].”
Expression of Regulatory Proteins in Choroid Plexus Changes in Early Stages of Alzheimer Disease
Krzyzanowska, A., García-Consuegra, I., Pascual, C., Antequera, D., Ferrer, I., & Carro, E. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000181 · Cited by 42 · cited 2×
“Up-regulation of 14-3-3 members have been detected in cortex and choroid plexus of AD patients using proteomic technologies [22, 43].”
Self-citationWei, Z., Sun, M., Liu, X., Zhang, J., & Jin, Y. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12740 · Cited by 39
Cited by
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J.-M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327745 · Cited by 1,533
Helicobacter pylori and extragastric diseases: A review
Gravina, A. G., Zagari, R. M., Musis, C. D., Romano, L., Loguercio, C., & Romano, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3204 · Cited by 328
Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease
Drummond, E., Nayak, S., Faustin, A., Pires, G., Hickman, R. A., Askenazi, M., Cohen, M., Haldiman, T., Kim, C., Han, X., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1691-0 · Cited by 239
Lachén-Montes, M., Mendizuri, N., Ausín, K., Pérez-Mediavilla, A., Azkargorta, M., Iloro, I., Elortza, F., Kondo, H., Ohigashi, I., Ferrer, I., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00452 · Cited by 12
Self-citationA reappraisal on amyloid cascade hypothesis: The role of chronic infection in Alzheimer’s disease
Phuna, Z. X., & Madhavan, P. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2045290 · Cited by 12
Metadata
- Authors
- Zelaya, M. V., Pérez-Valderrama, E., de Morentin, X. M., Tuñon, T., Ferrer, I., Luquin, M. R., Fernandez-Irigoyen, J., & Santamaría, E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-28
- Volume
- 6
- Issue
- 37
- Pages
- 39437-39456
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1882821985
- Cited by
- 67
- References
- 15
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.